Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.
chronic myeloid leukemia
protein kinases
synthetic lethality
tyrosine kinase inhibitors
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
11
2021
accepted:
05
01
2022
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
5
2
2022
Statut:
epublish
Résumé
Protein kinases (PKs) play crucial roles in cellular proliferation and survival, hence their deregulation is a common event in the pathogenesis of solid and hematologic malignancies. Targeting PKs has been a promising strategy in cancer treatment, and there are now a variety of approved anticancer drugs targeting PKs. However, the phenomenon of resistance remains an obstacle to be addressed and overcoming resistance is a goal to be achieved. Chronic myeloid leukemia (CML) is the first as well as one of the best examples of a cancer that can be targeted by molecular therapy; hence, it can be used as a model disease for other cancers. This review aims to summarize up-to-date knowledge on the main mechanisms implicated in resistance to PK inhibitory therapies and to outline the main strategies that are being explored to overcome resistance. The importance of molecular diagnostics and disease monitoring in counteracting resistance will also be discussed.
Identifiants
pubmed: 35115784
doi: 10.2147/OTT.S289306
pii: 289306
pmc: PMC8800859
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
103-116Informations de copyright
© 2022 De Santis et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Curr Med Chem. 2010;17(25):2804-21
pubmed: 20586715
Haematologica. 2012 Jun;97(6):907-14
pubmed: 22207690
Oncologist. 2011;16(6):868-76
pubmed: 21632458
Mol Cancer. 2018 Feb 19;17(1):49
pubmed: 29455643
Int J Mol Sci. 2019 Dec 05;20(24):
pubmed: 31817512
J Hematol Oncol. 2019 Apr 23;12(1):39
pubmed: 31014376
Nature. 2010 Jan 28;463(7280):501-6
pubmed: 20072125
Blood. 2013 Jan 17;121(3):489-98
pubmed: 23223358
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Cancer Cell. 2014 Sep 8;26(3):428-442
pubmed: 25132497
Cancer Res. 2006 Jul 1;66(13):6468-72
pubmed: 16818614
Science. 2001 Aug 3;293(5531):876-80
pubmed: 11423618
Leukemia. 2016 Jul;30(7):1615-9
pubmed: 26867670
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Acta Haematol. 2002;107(2):76-94
pubmed: 11919388
Genes Cancer. 2010 Apr;1(4):346-59
pubmed: 20798787
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6649-53
pubmed: 2204061
J Clin Invest. 2007 Sep;117(9):2562-9
pubmed: 17710227
Oncogene. 2001 Sep 27;20(43):6188-95
pubmed: 11593427
Ann Hematol. 2015 Apr;94 Suppl 2:S107-21
pubmed: 25814077
BMC Cancer. 2016 Aug 02;16:572
pubmed: 27485109
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12
pubmed: 16997913
Science. 2004 Jul 16;305(5682):399-401
pubmed: 15256671
Blood. 2000 Jun 1;95(11):3498-505
pubmed: 10828035
Leuk Lymphoma. 2011 Nov;52(11):2139-47
pubmed: 21718141
Blood. 2003 Jan 15;101(2):690-8
pubmed: 12509383
Cancer Cell. 2005 Feb;7(2):129-41
pubmed: 15710326
J Clin Invest. 2011 Jan;121(1):396-409
pubmed: 21157039
Leukemia. 2016 Jul;30(7):1493-501
pubmed: 27044711
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
Pharmacol Res. 2016 Jan;103:26-48
pubmed: 26529477
J Med Chem. 2018 Sep 27;61(18):8120-8135
pubmed: 30137981
Blood. 2005 Apr 1;105(7):2640-53
pubmed: 15618470
Nature. 1973 Jun 1;243(5405):290-3
pubmed: 4126434
Leukemia. 2018 Oct;32(10):2288-2291
pubmed: 29654270
Leukemia. 2021 Jul;35(7):2102-2107
pubmed: 33262525
Leuk Res. 2014 Jan;38(1):10-20
pubmed: 24131888
Leukemia. 2008 Feb;22(2):445-7
pubmed: 17690695
Science. 1990 Feb 16;247(4944):824-30
pubmed: 2406902
Cancer Res. 2008 Dec 1;68(23):9809-16
pubmed: 19047160
Leukemia. 2017 May;31(5):1253-1254
pubmed: 28465516
Cancer Cell. 2011 Dec 13;20(6):715-27
pubmed: 22169110
Blood. 2000 Aug 1;96(3):1070-9
pubmed: 10910924
Oncol Rep. 2011 Aug;26(2):471-8
pubmed: 21567097
Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10
pubmed: 12783368
Nature. 2017 Mar 30;543(7647):733-737
pubmed: 28329763
Cancer Cell. 2019 Oct 14;36(4):431-443.e5
pubmed: 31543464
Eur J Haematol. 2009 Apr;82(4):292-300
pubmed: 19191867
Blood. 2008 Apr 1;111(7):3821-9
pubmed: 18235045
J Natl Cancer Inst. 1960 Jul;25:85-109
pubmed: 14427847
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S120-8
pubmed: 26297264
Cell. 1984 Jan;36(1):93-9
pubmed: 6319012
Haematologica. 2007 Apr;92(4):437-9
pubmed: 17488653
Pharmacol Res. 2021 Jul;169:105660
pubmed: 33971270
J Exp Clin Cancer Res. 2019 May 23;38(1):216
pubmed: 31122263
Leukemia. 2005 Oct;19(10):1774-82
pubmed: 16136169
Pharmacol Res. 2015 Oct;100:1-23
pubmed: 26207888
J Cell Biochem. 2017 Nov;118(11):3968-3975
pubmed: 28401599
Blood. 2013 Aug 29;122(9):1634-48
pubmed: 23794064
Leukemia. 2011 Mar;25(3):463-72
pubmed: 21183952
Clin Cancer Res. 2005 Jul 1;11(13):4941-7
pubmed: 16000593
Cancer Res. 2006 Dec 1;66(23):11314-22
pubmed: 17114238
Expert Rev Anticancer Ther. 2008 Jun;8(6):853-64
pubmed: 18533795
Blood. 2003 Mar 15;101(6):2368-73
pubmed: 12609962
Haematologica. 2016 Jul;101(7):830-8
pubmed: 27102501
Blood. 2006 Jul 15;108(2):697-704
pubmed: 16597591
EMBO J. 1990 Apr;9(4):1069-78
pubmed: 1691092
Blood. 2006 Jul 15;108(2):678-84
pubmed: 16543472
Int J Mol Sci. 2021 Jun 30;22(13):
pubmed: 34209376
Cancer Res. 2005 Oct 1;65(19):8912-9
pubmed: 16204063
Haematologica. 2018 Jan;103(1):e10-e12
pubmed: 28983061
Blood. 2011 Aug 4;118(5):1208-15
pubmed: 21562040
Leukemia. 2007 Jun;21(6):1267-75
pubmed: 17519960
J Clin Invest. 2017 Jun 1;127(6):2392-2406
pubmed: 28481221
J Clin Oncol. 2010 Jun 1;28(16):2761-7
pubmed: 20421539
Hematol Oncol. 2020 Apr;38(2):201-203
pubmed: 31990987
Science. 1976 Oct 1;194(4260):23-8
pubmed: 959840
J Cancer Res Clin Oncol. 2015 May;141(5):887-99
pubmed: 25367136
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3550-5
pubmed: 24550512
Nature. 1983 Nov 17-23;306(5940):239-42
pubmed: 6316147
Cancer Res. 2002 Aug 1;62(15):4236-43
pubmed: 12154025
Nat Struct Mol Biol. 2008 Oct;15(10):1109-18
pubmed: 18794843
Oncogene. 2002 Oct 17;21(47):7137-46
pubmed: 12370803
Blood. 2011 Dec 22;118(26):6760-8
pubmed: 22039253
Int J Cancer. 1976 Jul 15;18(1):24-30
pubmed: 1065618
J Cell Physiol Suppl. 1984;3:179-91
pubmed: 6589229
Nat Rev Drug Discov. 2021 Nov;20(11):839-861
pubmed: 34354255
Blood. 2012 Feb 9;119(6):1501-10
pubmed: 22184410
J Natl Cancer Inst. 2008 Jul 2;100(13):926-39
pubmed: 18577747
J Natl Compr Canc Netw. 2020 Oct 01;18(10):1385-1415
pubmed: 33022644
Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):
pubmed: 34750265
Cancer Genet Cytogenet. 2002 Nov;139(1):30-3
pubmed: 12547154
Oncotarget. 2016 Apr 19;7(16):21982-90
pubmed: 26980736
Blood. 2007 Dec 1;110(12):4064-72
pubmed: 17761829
Oncologist. 2016 May;21(5):626-33
pubmed: 27032870
Leukemia. 2002 Nov;16(11):2190-6
pubmed: 12399961
Leukemia. 2010 Nov;24(11):1962-5
pubmed: 20811406
J Hematol Oncol. 2018 Jun 20;11(1):84
pubmed: 29925402
Pharmacogenomics. 2012 Aug;13(11):1271-84
pubmed: 22920397
Leukemia. 2017 Jan;31(1):75-82
pubmed: 27416909